| Similar Articles |
|---|
 |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.   |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
The Motley Fool
October 7, 2010
Anand Chokkavelu |
How Johnson & Johnson Really Makes Money Hint: It's not Tylenol. |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
The Motley Fool
March 11, 2011
Brian Orelli |
Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
September 29, 2011
Brian Orelli |
Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson. |
The Motley Fool
April 15, 2011
Brian Orelli |
Dark Clouds Lift Over Pharma Dispute The case of who bought whom in the Merck -Schering-Plough deal has ended in a draw. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
August 24, 2009
Brian Orelli |
J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell. |
The Motley Fool
November 21, 2008
Brian Orelli |
Manufacturing Pain Johnson & Johnson has plenty of it. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
March 31, 2011
Brian Orelli |
Johnson & Johnson Hires a Babysitter J&J tries to turn the OTC business around; the McNeil Consumer Health care unit will now be headed up by Patrick Mutchler, previously the head of the health-care giant's baby products.. |
The Motley Fool
May 6, 2010
Brian Orelli |
Johnson & Johnson, What Have You Done? We're not sure, but Congress wants to find out. The House Committee on Oversight and Government Reform launched an investigation yesterday into the recall JNJ announced last week. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
September 28, 2009
Brian Orelli |
The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
November 13, 2007
Brian Orelli |
Another Punch in the Nose for Pfizer The FDA clears ZYRTEC-D for over-the-counter sales; marketing of the medication will now switch hands from Pfizer to Johnson & Johnson. Investors, take note. |
The Motley Fool
January 20, 2009
Brian Orelli |
Johnson & Johnson Nimble ... for Now The health-care giant reports increasing earnings, despite falling revenue. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
March 17, 2009
Brian Orelli |
Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace. |
The Motley Fool
June 30, 2009
Brian Orelli |
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
January 20, 2004
Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. |
The Motley Fool
May 22, 2009
Brian Orelli |
J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs. |
The Motley Fool
June 28, 2011
Brian Orelli |
HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments. |
